(CTMX) Probody™ Pipeline Data to be Presented at 2015 AACR-NCI-EORTC

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2015  — CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company developing Probody™ therapeutics for the treatment of cancer, today announced that preclinical results from its Probody therapeutics pipeline have been accepted for presentation at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference will take place November 5-9 at the Hynes Convention Center in Boston.

Therapeutics developed with CytomX’s Probody platform are designed to be active in the tumor while sparing healthy tissue. This design is intended to avoid the toxicities that have been seen with many potent cancer therapies. CytomX’s preclinical pipeline of wholly-owned and partnered programs includes Probody cancer immunotherapies, Probody drug conjugates and Probody bispecifics.

 

Investor Event and Webcast
CytomX will host a live event with webcast on Sunday, November 8, at approximately 6:30 p.m. EST to review the data being presented at the conference and provide a business and pipeline update. The webcast can be accessed live or in archived form under “News & Events” in the Investors & News section of the company’s website at www.cytomx.com.

About CytomX Therapeutics
CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform. The company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. CytomX believes that its Probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and T-cell-recruiting bispecific antibodies. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. Probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, such as CD166, that are difficult to drug without causing damage to healthy tissues, or toxicities. In addition to its proprietary programs, CytomX is collaborating with strategic partners including Bristol-Myers Squibb Company, Pfizer Inc. and ImmunoGen, Inc. For more information, visit www.cytomx.com.

Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond our control, and may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements. Accordingly, you should not rely on any of these forward-looking statements. Our Probody therapeutics are in preclinical development, and the process by which a preclinical technology could potentially lead to an approved product is long and subject to significant risks and uncertainties. Applicable risks and uncertainties include those relating to our preclinical research and development and other risks identified under the heading “Risk Factors” included in our filings with the SEC. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.

Media Contacts:
Canale Communications
Ian Stone
ian@canalecomm.com
619-849-5388

Investor Contacts:
Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973